| Patient | Jackie Robinson |
|---|---|
| Date of birth | 1974-01-31 |
| Identifiers | MRN HR-ML037-SYN; SSN (made up) 000-37-2286 |
| Document date | 2026-10-26 |
| Author | Marcus Delacroix-Hale, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Three-month review: A1c, urine albumin, lipids, eyes after laser treatment, heart, legs, grief, and a GLP-1 receptor agonist. [S]
Mr. Robinson returns three months after his first visit. He had the third injections in both eyes a month ago and laser treatment to the right eye nearly three weeks ago. Dr. Ostrowski-Lane reports that the blood has largely cleared, the new vessels are regressing, the macular swelling is much less (central subfield 318 microns right and 334 left at the last scan), and his acuity has improved to 52 letters right and 68 left; she judges the retina stable enough to start a GLP-1 receptor agonist at a low dose with monthly review. The low-vision visit gave him magnifiers and better lighting. He walks two and a half blocks before calf pain in the exercise program. No chest pain. No low blood sugar. His PSA, HIV and hepatitis C tests were normal. He says the counseling helps and he sleeps better, though the loss is with him every day. [S]
| Element | Detail |
|---|---|
| Eyes | Three injections both eyes and laser right eye; acuity 52 and 68 letters |
| Walking | Two and a half blocks |
| Screening | PSA, HIV and hepatitis C normal |
| Mood | PHQ-9 6 |
| System | Result | Finding |
|---|---|---|
| Eyes | Positive | Vision clearer; reads large print with a magnifier |
| Cardiovascular | Positive | Calf pain after two and a half blocks; no chest pain |
| Endocrine | Negative | No low blood sugar |
| Gastrointestinal | Negative | No nausea or change in bowel habit |
| Psychiatric | Positive | Grieving; sleeping better |
5 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Metformin 1,000 mg oral tablet, one tablet twice daily with meals | One tablet twice daily with meals | Oral route | 2025-03-03 | active | S |
| Insulin glargine 100 units/mL pen, 30 units at bedtime, adjusted by the written plan: 2 units each week while fasting glucose is above 160 mg/dL, and 4 units less for any reading below 70 | At bedtime, by the gradual titration plan | Subcutaneous route | 2025-03-03 | active | S |
| Lisinopril 20 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2025-03-03 to 2026-07-29 | completed | S |
| Atorvastatin 80 mg oral tablet, one tablet daily (increased from 40 mg at intake) | One tablet daily | Oral route | 2026-07-27 | active | S |
| Aspirin 81 mg delayed-release oral tablet, one tablet daily | One tablet daily | Oral route | 2025-03-03 | active | S |
| Glucagon 3 mg nasal powder, one spray into the nose for severe low blood sugar; may repeat once after 15 minutes | As needed for severe low blood sugar | Nasal route | 2026-07-27 | active | S |
| Metoprolol succinate extended-release 25 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2026-08-12 | active | S |
| Nitroglycerin 0.4 mg sublingual tablet, one under the tongue for chest pain, repeated every five minutes up to three; call 911 if pain is not better five minutes after the first | As needed for chest pain, up to three doses | Sublingual route | 2026-08-12 | active | S |
| Lisinopril 40 mg oral tablet, one tablet daily; hold on days of vomiting, diarrhea or not eating | One tablet daily, with sick-day rules | Oral route | 2026-07-29 | active | S |
| Empagliflozin 10 mg oral tablet, one tablet daily; hold on days of vomiting, diarrhea or not eating, and before surgery or a colonoscopy preparation | One tablet daily, with sick-day rules | Oral route | 2026-07-29 | active | S |
| Ezetimibe 10 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2026-10-26 | active | S |
| Dulaglutide 0.75 mg/0.5 mL pen, one injection under the skin once a week; dose to rise to 1.5 mg after at least four weeks only if the retina remains stable | Once a week, same day each week | Subcutaneous route | 2026-10-26 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-10-26 | Body height | 180 | cm | S |
| 2026-10-26 | Body weight | 101.4 | kg | S |
| 2026-10-26 | Body mass index (BMI) [Ratio] | 31.3 | kg/m2 | S |
| 2026-10-26 | Systolic blood pressure | 126 | mm[Hg] | S |
| 2026-10-26 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 2026-10-26 | Heart rate | 60 | /min | S |
| 2026-10-26 | Respiratory rate | 16 | /min | S |
| 2026-10-26 | Body temperature | 36.6 | Cel | S |
| 2026-10-26 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-10-26 | Hemoglobin A1c/Hemoglobin.total in Blood | 9.2 | % | Below 5.7% is normal; his first goal below 8%, then below 7%, lowered gradually | High | S |
| 2026-10-26 | Albumin/Creatinine [Mass Ratio] in Urine | 54 | mg/g | Below 30 mg/g normal (A1); 30 to 300 moderately increased (A2) | High | S |
| 2026-10-26 | Sodium [Moles/volume] in Serum or Plasma | 139 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-10-26 | Potassium [Moles/volume] in Serum or Plasma | 4.7 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-10-26 | Creatinine [Mass/volume] in Serum or Plasma | 1.18 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 2026-10-26 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 74 | mL/min/{1.73_m2} | 90 or higher is normal; 60 to 89 is mildly decreased (G2) | Low | S |
| 2026-10-26 | Cholesterol [Mass/volume] in Serum or Plasma | 150 | mg/dL | <=199 mg/dL | Normal | S |
| 2026-10-26 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 74 | mg/dL | Goal below 55 mg/dL with atherosclerotic disease | Normal | S |
| 2026-10-26 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 40 | mg/dL | >=40 mg/dL | Normal | S |
| 2026-10-26 | Triglyceride [Mass/volume] in Serum or Plasma | 180 | mg/dL | <=149 mg/dL | High | S |
| 2026-10-26 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 30 | U/L | 7-55 U/L | Normal | S |
| 2026-10-26 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 6 | {score} | S |
Vital signs recorded on 2026-10-26; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; blood pressure 126/76, pulse 60; weight 101.4 kg |
| Cardiovascular | Regular rhythm; no ankle swelling |
| Feet | Heel healed; no new breaks; fitted shoes |
| Psychiatric | Composed; no thoughts of self-harm |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Blurred vision in both eyes, worse over two months, with new floaters in the right eye for four days; acuity by Snellen chart 20/200 right and 20/80 left; undilated view poor on the right; urgent retina examination arranged | resolved | confirmed | H53.8 | S — Synthetic presenting finding, superseded by the retinal diagnosis two days later. |
| Tightness in the chest on climbing stairs for two months, easing with rest; ECG without acute change; cardiology evaluation with a stress test arranged | resolved | confirmed | R07.89 | S — Synthetic presenting finding, superseded by the coronary diagnosis after the stress test. |
| Type 2 diabetes for about fifteen years, on metformin and basal insulin, with hyperglycemia (A1c 10.4%) | active | confirmed | E11.65 | S — Synthetic modern episode linked to his documented diabetes. |
| Proliferative diabetic retinopathy in both eyes with center-involving diabetic macular edema (central subfield 412 microns right, 468 left); best-corrected acuity 35 letters right and 56 letters left | active | confirmed | E11.3513 | S — Synthetic retinal findings anchored to his documented loss of vision. |
| Vitreous hemorrhage in the right eye from proliferative retinopathy; retina attached on ultrasound | active | confirmed | H43.11 | S — Synthetic finding. |
| Hypertension with chronic kidney disease, above goal on lisinopril 20 mg (152/92 mmHg) | active | confirmed | I12.9 | S — Synthetic modern episode linked to his documented high blood pressure. |
| Diabetic kidney disease with albuminuria (urine albumin-to-creatinine ratio 86 mg/g, also raised last year) and eGFR 79 | active | confirmed | E11.22 | S — Synthetic kidney findings. |
| Chronic kidney disease G2 A2 | active | confirmed | N18.2 | S — Synthetic kidney finding. |
| Peripheral artery disease of both legs with calf pain after about one block of walking; faint foot pulses | active | confirmed | E11.51 | S — Synthetic modern episode linked to the documented artery damage in his legs. |
| Diabetic peripheral neuropathy: loss of protective sensation in both feet on monofilament testing | active | confirmed | E11.42 | S — Synthetic modern episode linked to the documented nerve damage in his legs. |
| History of two mild strokes a year ago, without lasting weakness | active | confirmed | Z86.73 | S — Synthetic modern coding of the documented strokes. |
| Hyperlipidemia: LDL 142 mg/dL on atorvastatin 40 mg, far above the goal below 55 mg/dL | active | confirmed | E78.5 | S — Synthetic laboratory finding. |
| Bereavement: his eldest son died in a car crash six weeks ago | active | confirmed | Z63.4 | S — Synthetic modern coding of a documented loss; grief is treated as grief, not as a disorder. |
| Coronary artery disease with stable angina on climbing stairs: a small reversible inferior perfusion defect on regadenoson stress imaging, ejection fraction 56%; medical therapy chosen with cardiology | active | confirmed | I25.119 | S — Synthetic coronary diagnosis anchored to his documented heart disease; no heart attack is recorded before the episode. |
| Friction blister of the right heel from new shoes, unroofed, 2.5 by 2 cm, clean base, without infection, in a neuropathic foot with peripheral artery disease | resolved | confirmed | S90.821A | S — Synthetic intercurrent problem at an unscheduled visit; it does not echo a documented event. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Blood pressure (seated, two readings, large cuff) | Every visit | Completed today | 126/76 |
| Examination | Weight and BMI | Every visit | Completed today | 101.4 kg, down 2.6 kg |
| Laboratory | Hemoglobin A1c | Every 3 months while not at goal or after a change | Completed today | 9.2%, from 10.4% |
| Laboratory | Urine albumin-to-creatinine ratio | Three to six months after a treatment change; then 1 to 4 times a year by risk | Completed today | 54 mg/g, from 86 |
| Laboratory | Potassium, creatinine and eGFR | Two to four weeks after starting or increasing an ACE inhibitor or SGLT2 inhibitor; then every 6 to 12 months | Completed today | Sodium 139, potassium 4.7 mmol/L; creatinine 1.18 mg/dL; eGFR 74 |
| Laboratory | Lipid panel | 4 to 12 weeks after starting or changing a statin; then yearly | Deferred | Late: the panel due 4 to 12 weeks after the atorvastatin increase was not ordered at the four-week visit and was drawn today, at thirteen weeks. No harm: LDL 74 mg/dL, total cholesterol 150, HDL 40, triglycerides 180 mg/dL; ALT 30 U/L. Corrective action: follow-up lipids for today's ezetimibe booked before he left, at four to eight weeks |
| Imaging | Retina care: acuity, OCT, injections and laser | Monthly at the retina clinic while treating | Completed today | Retina report reviewed: third injections and right-eye laser done; central subfield 318 and 334 microns; acuity 52 and 68 letters; monthly review continues |
| Medication safety | Retinopathy safety with a GLP-1 receptor agonist | Retina review within a month of starting and before each dose increase | Completed today | Started only with the retina specialist's agreement; lowest dose; monthly review booked |
| Imaging | Ankle-brachial index | At diagnosis of peripheral artery disease; then with any change in symptoms or a wound | Not indicated | No change in symptoms and no wound; repeat only if symptoms change |
| Examination | Foot inspection; comprehensive foot examination | Every visit with loss of sensation; comprehensive examination yearly | Completed today | Heel healed; no new breaks |
| Examination | Angina review | Every visit | Completed today | No angina on metoprolol |
| Survey | Depression screen (PHQ-9) | At intake and at three months while grieving; at least yearly | Completed today | PHQ-9 6, item 9 scored 0 |
| Laboratory | Vitamin B12 on metformin | Periodically on long-term metformin | Up to date | 380 pg/mL at intake |
| Medication safety | Medicine safety: low blood sugar, sick-day rules, genital infection, dizziness, cost | Every visit | Completed today | No low blood sugar; sick-day rules reviewed for the colonoscopy preparation |
| Medication safety | COVID-19 and hepatitis B vaccines | COVID-19 each autumn; hepatitis B for adults with diabetes under 60 | Completed today | Both given; hepatitis B dose 2 in one month; zoster dose 2 due |
| Self-management | Low-vision services and diabetes tools he can use | When vision limits daily life | Completed today | Low-vision evaluation done: magnifiers, lighting and voice tools |
Goal progress:
Immunizations given today: COVID-19 vaccine, mRNA, this season; Hepatitis B vaccine (HepB-CpG), dose 1 of 2 [S]
Guideline basis: 6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026 (2026); 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2026 (2026); 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2026 (2026); 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes-2026 (2026); 12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes-2026 (2026); 5. Facilitating Positive Health Behaviors and Well-being to Improve Health Outcomes: Standards of Care in Diabetes-2026 (2026); Diabetic Retinopathy Preferred Practice Pattern (2025); Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6) (2016); 2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease (2024); 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease (2023); 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025); KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); CMID: Clinical Monitoring Intelligence Database, diabetes type 2, hypertension, hyperlipidemia, ischemic heart disease, chronic kidney disease and depression monographs (2026); Depression and Suicide Risk in Adults: Screening (2023); Adult Immunization Schedule by Age (2026); Practical guidelines on the prevention and management of diabetes-related foot disease (IWGDF 2023 update) (2023)
Follow-up: Retina clinic monthly. Lipids in four to eight weeks. Hepatitis B dose 2 in one month. Colonoscopy next month with the written preparation plan. Review in three months with the A1c. Call for nausea or vomiting that stops him drinking, any change in vision, chest pain, or a skin break on the feet. [S]